UK 05:48 Sunday, 4 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Hello Share Shepherds. A small medical pioneer I’ve commended to your further study before is Feedback (FDBK). It has some clever software to help hospital doctors do their job better. However, the share hasn’t exactly taken off, yet. Never mind, now comes some news which might kick start a better performance.
Hello, Share Followers. A company for which I have high hopes still to be realised is Feedback plc (FDBK). On the face of it this AIM company which enables doctors and surgeons to see what’s going on in the human body should enjoy a buoyant share price. Yet it’s been disappointing for some time now. However, with much more focus on medical services these days, perhaps its time has come...
Hello, Share Prompters. A medical venture I’ve invested in for years and which has usually disappointed is Feedback plc (FDBK). It always appears to me to have huge potential that doesn't seem to have been followed through. Perhaps the company needs more marketing skills. Any road up, it's just had some good news that the share price seems yet to have fully reflected...
Hello, Share Tweakers. It’s with some unease that I suggest you take a look at today’s choice. That’s because Tom has said that he doesn't rate it. And only a fool disregards his astute analysis. But I am sometimes a momentum player, and the company I have in mind could turn out to be a short-term winner...
Writing last week on Feedback plc (FDBK), I concluded with the combination of the noted financials, Bleepa still in development (i.e. very much yet to be “revolutionising clinical messaging”!) and a market cap of sub £5 million, meaning it at best looking like discounted placing ahoy, currently natch avoid / sell. Now “Proposed placing and subscription to raise £2m”…
A “Statement re Online Commentary” from Feedback plc (FDBK) which “confirms that, in order to develop BleepaTM, the company's clinical messaging product, it is currently working on completing a placing of new shares”…
To be clear, I don’t believe Malcolm has ripped off shareholders in an investment trust he manages by stuffing it full of unquoted stocks to save his bacon elsewhere; however, he does seem to have picked up a few of the “star fund manager’s” bad habits when it comes to a stock, namely Feedback (FDBK).
Hello, Shares Lovelies. It’s time to revisit a favourite penny share of mine. Though it’s not exactly repaid my loyalty in the last year. Nevertheless, I feel that, given its potential and support in 40 countries, the present lowly share price is unfair.
Hello, Share Purloiners. There was a welter of off-stage discussion at the last mouth-watering UK Investor Show on April 1st about Feedback (FDBK). It’s another of those AIM-listed medical pioneers, looking to develop new life-saving techniques.
Hello Share Bottlers. Yesterday I took a look at Avacta (AVCT). Now I bring to your notice another medical pioneer, Feedback (FDBK).
Hello Share Rattlers. Quite a few of my friends face a grim Christmas. They are undergoing radio and chemo treatment for cancer. Is it me, or is the number of cases growing even faster than normal?
